Objective: To investigate the male urogenital tract mycoplasma infection and drug-resistance evolution in 2001 and 2003.
Methods: The results of mycoplasma culture and drug sensitivity tests were explored in 2001 and 2003, and the differences of drug sensitivity between the two years were analysed.
Results: Of the 109 mycoplasma positive cases in 2001, 86.2% were infected with Ureaplasma urealyticum (Uu), 3.8% with Mycoplasma hominis (Mh), 10.1% with both Uu and Mh; and of the 134 mycoplasma positive cases in 2003, Uu infection accounted for 79.1%, Mh infection 4.48% and Uu and Mh infection 16.4%. Compared with 2001, the drug-resistance rates to roxithromycin, azithromycin, levofloxacin, ofloxacin and clindamycin rose obviously in 2003; but the drug-resistance rates to josamycin, minomycin and doxycycline did not change significantly. As far as the drug sensitivity rate is concerned, josamycin ranked the first, and doxycycline the second.
Conclusions: Mycoplasma was a high rate of drug-resistance, and the drug sensitivity evolves with the time. Treatment for mycoplasma should be based on the results of drug sensitivity tests. Josamycin can be used as the first choice.